Observational studyJournal of hematopathology2026
Prognostic value of combined digital PCR and multiparametric flow cytometry monitoring MRD in non-transplant acute myeloid leukemia.
Observational study in Journal of hematopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the synergistic prognostic value of digital PCR (dPCR)-based multigene measurable residual disease (MRD) monitoring combined with multiparametric flow cytometry (MFC) in patients with non-transplant acute myeloid leukemia (AML).
methodsThis observational cohort study analyzed 86 newly diagnosed AML patients (excluding APL) at the Affiliated Hospital of Hebei University (January 2018-May 2025). MRD was assessed using MFC (threshold: 0.1%) and dPCR (variant allele frequency [VAF] < 0.001%). Outcomes included relapse-free survival (RFS), overall survival (OS), and cumulative relapse rates.
resultsWith a median follow-up time of 18.5 months, dPCR-MRD negativity predicted superior 2-year RFS (67.1% vs 42.3%, HR = 0.365, P = 0.003). Combined MFC/dPCR negativity further enhanced prognostic discrimination (2-year RFS: 68.2% vs 40.5%, HR = 0.323, P = 0.001). Subgroup analysis revealed MFC-driven RFS benefits in intensive chemotherapy (72.2% vs 33.3%, HR = 0.180, P = 0.014), while dual-platform monitoring showed trends favoring non-intensive regimens (58.7% vs 31.7%, HR = 0.407, P = 0.051).
conclusiondPCR-MRD monitoring complements MFC for the stratification of risk of relapse, particularly among non-transplant AML patients. Dual-platform integration improves predictive accuracy, supporting personalized MRD-guided strategies.
Indexed as
Identifiers
41979735What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.